Compare FBK & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBK | QURE |
|---|---|---|
| Founded | 1906 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2016 | 2013 |
| Metric | FBK | QURE |
|---|---|---|
| Price | $51.70 | $19.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $63.38 | $58.14 |
| AVG Volume (30 Days) | 285.7K | ★ 1.7M |
| Earning Date | 10-13-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ 3.43 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $12.93 | $39.49 |
| Revenue Next Year | $6.20 | $402.79 |
| P/E Ratio | $15.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.67 | $8.73 |
| 52 Week High | $62.66 | $51.72 |
| Indicator | FBK | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 31.36 |
| Support Level | $50.52 | $13.96 |
| Resistance Level | $53.56 | $26.07 |
| Average True Range (ATR) | 1.27 | 1.70 |
| MACD | -0.33 | -0.05 |
| Stochastic Oscillator | 0.61 | 0.49 |
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates majority of revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.